YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study by Senetta, Rebecca et al.
RESEARCH ARTICLE
YKL-40/c-Met Expression in Rectal Cancer
Biopsies Predicts Tumor Regression following
Neoadjuvant Chemoradiotherapy: A Multi-
Institutional Study
Rebecca Senetta1☯, Eleonora Duregon2☯, Cristina Sonetto3, Rossella Spadi3,
Massimiliano Mistrangelo4, Patrizia Racca3, Luigi Chiusa1, Fernando H. Munoz2,
Umberto Ricardi2, Alberto Arezzo4, Adele Cassenti1, Isabella Castellano1, Mauro Papotti2,
Mario Morino4, Mauro Risio5, Paola Cassoni1*
1 Department of Medical Sciences, University of Turin, Turin, Italy, 2 Department of Oncology, University of
Turin, Turin, Italy, 3 SSCVDColorectal Cancer Unit, City of Health and Science Hospital of Turin, Turin, Italy,
4 Digestive and Colorectal Surgery, Centre of Minimal Invasive Surgery, University of Turin, Turin, Italy,
5 Candiolo Cancer Institute—FPO (Fondazione del Piemonte per l'0ncologia), IRCCS (Istituto di Ricovero e
Cura a Carattere Scientifico), Candiolo, Turin, Italy
☯ These authors contributed equally to this work.
* paola.cassoni@unito.it
Abstract
Background
Neoadjuvant chemo-radiotherapy (CRT) followed by surgical resection is the standard
treatment for locally advanced rectal cancer, although complete tumor pathological regres-
sion is achieved in only up to 30% of cases. A clinicopathological and molecular predictive
stratification of patients with advanced rectal cancer is still lacking. Here, c-Met and YKL-40
have been studied as putative predictors of CRT response in rectal cancer, due to their re-
ported involvement in chemoradioresistance in various solid tumors.
Material and Methods
Amulticentric study was designed to assess the role of c-Met and YKL-40 expression in
predicting chemoradioresistance and to correlate clinical and pathological features with
CRT response. Immunohistochemistry and fluorescent in situ hybridization for c-Met were
performed on 81 rectal cancer biopsies from patients with locally advanced rectal adenocar-
cinoma. All patients underwent standard (50.4 gy in 28 fractions + concurrent capecitabine
825 mg/m2) neoadjuvant CRT or the XELOXART protocol. CRT response was documented
on surgical resection specimens and recorded as tumor regression grade (TRG) according
to the Mandard criteria.
Results
A significant correlation between c-Met and YKL-40 expression was observed (R = 0.43).
The expressions of c-Met and YKL-40 were both significantly associated with a lack of
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complete response (86% and 87% of c-Met and YKL-40 positive cases, p< 0.01 and p =
0.006, respectively). Thirty of the 32 biopsies co-expressing both markers had partial or ab-
sent tumor response (TRG 2-5), strengthening their positive predictive value (94%). The ex-
clusive predictive role of YKL-40 and c-Met was confirmed using a multivariate analysis (p =
0.004 and p = 0.007 for YKL-40 and c-Met, respectively). TRG was the sole morphological
parameter associated with poor outcome.
Conclusion
c-Met and YKL-40 expression is a reliable predictor of partial/absent response to neoadju-
vant CRT in rectal cancer. Targeted therapy protocols could take advantage of prior evalua-
tions of c-MET and YKL-40 expression levels to increase therapeutic efficacy.
Background
Neoadjuvant chemoradiotherapy (CRT) followed by surgical resection according to the princi-
ple of total mesorectal excision is the standard treatment for locally advanced mid or low rectal
cancer, i.e., T3-T4 lesions and/or the presence of suspected regional metastatic lymph nodes
[1–4]. This approach, which allows high rates of tumor resectability and sphincter-saving pro-
cedures [5], determines tumor downstaging in 28–62%[5,6] of such cases and improves local
control[7]. However, irrespective of the tumor stage, treatment response is very heterogeneous,
as complete tumor pathological regression is achieved in 10–30% of cases[6,8] and many rectal
cancer patients are resistant to preoperative CRT[9]. Therefore, predicting neoadjuvant CRT
response may allow a more rational selection of patients who will most likely benefit from this
therapy. Over the last two decades, many clinical, radiological and morphological[10–13] pa-
rameters, as well as molecular markers [14–21], have been investigated. Unfortunately, a panel
of markers or a gene classifier that is useful in predicting neoadjuvant CRT response has not
yet been established, and an extensive clinical validation is still needed [18,22–27]. Among pos-
sible markers, the glycoprotein YKL-40 [28] and the oncogene c-Met receptor tyrosine kinase
are prognostic and chemo- and radioresistance-related markers [29–34] and are candidates for
targeted therapy [28,29,31,32,35–42]. Furthermore, c-Met inhibitors were proven to increase
tumor cell radiosensitivity, enhancing the ability of radiation to inhibit tumor growth and inva-
siveness in tumor xenografts and in vitro [30,37,40]. Similarly, the combination of radiotherapy
and neutralizing YKL-40 antibodies showed a synergistic effect in inhibiting tumor vasculariza-
tion and the progression in in vivo models of glioblastoma[34]. However, their role as predic-
tive markers has not yet been tested in rectal cancer. Therefore, a multicentric study aimed at
assessing the role of c-Met and YKL-40 in predicting chemo- and radioresistance was designed
for 81 patients with locally advanced rectal adenocarcinoma.
Here, we show that a) c-Met and YKL-40 are independent predictors of poor response to
CRT and b) tumor regression grade (TRG), but neither c-Met nor YKL-40, is the sole prognos-
tic marker of shorter overall and disease survival.
Materials and Methods
Cases collection
Eighty-one rectal cancer pre-treatment endoscopic biopsies and their matched surgical speci-
mens were retrieved from consecutive cohorts from the archives of the pathology divisions of
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three Italian Institutions between January 2006 and December 2012: University of Torino at
Città della Salute e della Scienza (Molinette) Hospital of Turin (46 cases); San Luigi Hospital of
Orbassano (16 cases); and Institute for Cancer Research and Treatment of Candiolo (19 cases).
All patients had a locally advanced rectal adenocarcinoma eligible for neoadjuvant CRT
(cT3-T4 stage). Fifty-one patients (63%) received CRT according to a standard capecitabine
regimen (50.4 Gy in 28 fractions + concurrent capecitabine 825 mg/m2), whereas the remain-
ing 30 patients (37%) underwent a XELOXART trial (50,4 Gy in 28 fractions + capecitabine
825 mg/m2+ Oxaliplatin 60 mg)[4]. The CRT completion rate was 92.5% (75/81 patients). Six
patients stopped treatment due to gastrointestinal or cutaneous toxicity and, among them, 3
patients completed only the first three weeks of treatment. In all cases surgery was planned and
performed 6–8 weeks after the end of CRT. The study was submitted to and approved by the
Ethic Institutional Review Board for "Biobanking and use of human tissues for experimental
studies" of the Pathology Service of the Azienda Ospedaliera Città della Salute e della Scienza di
Torino, Torino, Italy. The project provided a verbal and not written informed consent from the
patients due to the retrospective approach of the study, which did not impact on their treat-
ment. All the cases were anonymously recorded. The Institutional Review Board approved this
consent procedure.
Histopathological evaluation
All hematoxylin and eosin (H&E)-stained slides available from biopsies and surgical specimens
were reviewed, and a representative paraffin block was selected for each case. Biopsy and surgi-
cal specimens of each patient were independently reviewed by two dedicated pathologists (RS
and PC), who confirmed all diagnoses. On the rectal pre-treatment biopsies, the tumor grade
(G1-G2-G3) and apoptosis were evaluated. Apoptosis was assessed by evaluating the apoptotic
bodies lining the basal membrane, and it was scored as negative (<25% per 100 viable cells) or
positive (> = 25% per 100 viable cells). Vascular invasion was not included among the histo-
pathological parameters analyzed since biopsy samples are usually superficial and small-sized
and therefore considered poorly reliable for the presence of neoplastic emboli. Response to
neoadjuvant CRT was established by a histopathological examination of surgically resected rec-
tal specimens using the tumor regression grade (TRG), according to Mandard criteria [43],
which are classified into five grades from TRG1 (complete regression) to TRG5 (no regression)
based on the presence of residual cancer cells and on the degree of fibrotic changes. To simplify
the analysis, complete tumor response (TRG1) was compared with partial/absent response
(TRG2-5).
Immunohistochemistry
Immunohistochemistry was performed in all but five cases of pre-treatment biopsies, which
had insufficient tissue from the rectal biopsy. Resected surgical specimens with residual cancer
(TRG2-5) were analyzed as well. Three ìm thick serial paraffin sections of each case were pro-
cessed by immunohistochemistry using an automated immunostainer (Ventana BenchMark
AutoStainer, Ventana Medical Systems, Tucson, AZ, USA) with antibodies against YKL-40
(Quidel Corporation, San Diego, CA, USA, rabbit polyclonal, diluted 1/400) and c-Met
(Abcam PLC, Cambridge, UK, rabbit polyclonal, diluted 1:200). The antigen retriewal step was
included in the automated programme. A biotin-free, dextran chain-based detection system
(EnVysion, Dako, Carpinteria, CA, USA) and diaminobenzidine (Ventana Medical Systems,
Tucson, AZ, USA) were used as the chromogen, according to standard protocols. Neoplastic
tissues were assembled on tissue microarrays, excluding the primary antibody and IgG-
matched serum, and were used as positive and negative controls.
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Staining interpretation and scoring system
All immunostained slides were analyzed independently by RS, AC and PC, who were blinded
to the clinical data. YKL-40 and c-Met staining was assessed as both categorical (negative or
positive if present in at least 1% of the neoplastic cells) and continuous variables (scored as
number of positive neoplastic cells). When positive, cells had a moderate to strong cytoplasmic
reactivity for both antibodies. In case of discrepancies, slides were reviewed using a multihead
microscope, and a consensus was reached.
c-Met Fluorescent in situ hybridization (FISH) analysis
c-Met FISH analysis was performed using the probe mixtures set, MET/CEP7 (Abbott Molecu-
lar, Des Plaines, IL, USA), in all biopsies with a positive c-Met immunostaining. FISH experi-
ments were carried out according to the manufacturer’s instructions as follows: 10 μl of probe
mixture was applied to each slide, which was immediately covered with a coverslip and sealed
with rubber cement. Slides were thoroughly co-denatured in the Hybrite System (Vysis, Dow-
ners Grove, IL, USA) at 73°C for 3 minutes and hybridized overnight at 37°C. A post-hybrid-
ization wash was performed in 2xSSC-0.3% NP-40 at 73°C for 3 minutes. Then, slides were
dehydrated and counterstained with DAPI I (4,6-diamidine-2-phenylindol, Vysis, Downers
Grove, IL, USA). An automated scanning station, MethaSystems (Carl Zeiss MetaSystems
Gbmh, Altlussheim, Germany), equipped with an AxioImager–Z1 epifluorescence microscope
was used to determine the c-Met gene status. Tumor areas with high signal quality and good
nuclei preservation were assessed. These areas were automatically scanned, and 10 different
consecutive focal planes were made for each FISH signal to form a single bidimensional image.
For traditional reading, the automatically acquired images were transferred to the Isis software
(Carl Zeiss MetaSystems Gbmh, Altlussheim, Germany) and stored in dedicated files. FISH
data were analyzed using previously described criteria, according to Capuzzo et al. [44].
Statistical Analysis
Correlations between YKL-40 and c-Met antibodies were made using the Chi-square test and
two-tailed Spearman’s test when considered categorical or continuous variables, respectively.
Clinico-pathological parameters for univariate analyses to determine predictors of the response
to CRT included tumor grade, apoptosis, YKL-40 and c-Met staining patterns. Fisher’s exact or
Chi-square tests were used. All parameters in the univariate analysis with a significant impact
on predicting CRT response were considered for multivariate analysis using the Cox propor-
tional hazard model. To analyze the prognostic impact of all pathological variables considered,
the univariate overall survival analysis was based on the Kaplan–Meier product limit estimate
of survival distribution. Unadjusted differences between survival curves were tested using the
log-rank test. All tests were performed using the Statistical Package for the Social Sciences ver-
sion 17 (SPSS Inc., Chicago, IL, USA). A significance level of p<0.05 was used.
Results
1) Clinicopathological data and pathological tumor response evaluated
according to Mandard TRG
The main clinical and pathological features of the whole series of 81 cases are summarized in
Table 1.
According to TNM staging, 20 cases (25%) had a post-CRT pathological T stage ypT0, 4
cases (5%) had ypT1, 20 cases had (25%) ypT2, 35 cases had (43%) ypT3 and 2 cases had (2%)
ypT4. Lymph node metastases were detected in 22 cases (27%). The clinical T stage (cT) was
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obtained in 74 cases (91%), and a T-downstaging after RCT was observed in 48 (65%) of them.
Applying the Mandard criteria to define the TRG, 20 cases (25%) had a complete pathological
tumor response to neoadjuvant CRT (TRG1-ypT0) on the surgically resected rectal specimens.
In the remaining 61 patients (75%), a partial or absent tumor response was observed, with 16
cases (20%) classified as TRG2, 22 cases (27%) classified as TRG3, 21 cases (26%) classified as
TRG4 and 2 cases (2%) classified as TRG5 (Fig 1).
The distribution of complete (TRG1) versus partial responders (TRG2-5) was similar in the
two subgroups of treatment (RT+capecitabine or XELOXART protocol).
2) Immunohistochemistry for YKL-40 and c-Met, FISH analyses and
clinicopathological correlates
Overall, YKL-40 tumor expression was observed in 47 (62%) cases, with a moderate or strong
immunostaining localized within the cytoplasm of neoplastic cells (Fig 2A and 2B), while
forty-three (56%) cases were positive for c-Met with a moderate or strong cytoplasmic reactivi-
ty (Fig 2A and 2C).
Both YKL-40 and c-Met tumor expression was retained in resected rectal specimens accord-
ing to their expression on endoscopic biopsies. c-Met FISH analysis was performed in all 43
c-Met-positive cases. No c-Met gene amplification was found, whereas nine (21%) cases dem-
onstrated low/high gene polisomy (Fig 2D). The expression of YKL-40 and c-Met was signifi-
cantly correlated when considered both continuous variables (r = 0.43 and p = 0.001) and
categorical variables (χ2 = 6.96; p = 0.01). YKL-40 was positive in moderately or poorly differ-
entiated cases (p = 0.018) and in those lacking inflammatory infiltrate (p = 0.01), whereas
c-Met was positively correlated with the absence of apoptosis (Table 2).
Table 1. Clinical pathological features of the 81 rectal cancer biopsies cases analyzed for YKL-40 and
c-Met.
Parameter
M/F ratio 1.79
Age, mean (years) [range] 63 [44–91]
Grade 1: 4
2: 66
3: 11
Mandard TRG 1: 20
2: 16
3: 22
4: 21
5: 2
Lymph node status (pN) 0: 59
1: 21
Disease status (lost to FU: 3) NED: 59
AWD: 18
DOD: 3
Local recurrence [median months] 11 [16]
Median overall survival (months) [range] 40 [6–79]
Median disease free survival (months) [range] 31 [5–78]
Abbreviations: F, female; M, male; TRG, tumor regression grade; FU, follow up; NED, no evidence of
disease; AWD, alive with disease; DOD, died of disease.
doi:10.1371/journal.pone.0123759.t001
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Fig 1. Distribution of patients according to TRG classes.
doi:10.1371/journal.pone.0123759.g001
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Fig 2. Representative examples of rectal carcinoma (A, Hematoxylin & Eosin, original magnification 200X) with mild to strong cytoplasmic
immunoreactivity for YKL-40 (B, original magnification 400X) and c-Met (C, original magnification 400X) and high c-Met gene polisomy by FISH
analysis.
doi:10.1371/journal.pone.0123759.g002
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3) Correlation of Mandard TRG with morphological,
immunohistochemical and molecular features (Table 3)
In a univariate analysis subdividing the entire series into complete (TRG1) or non-complete re-
sponders (TRG2-5), neither tumor grade nor the presence of apoptosis were detected on rectal
pre-treatment biopsies with TRG, indicating that none of these histological features proved
Table 2. YKL-40 and c-Met immunohistochemistry: clinical and pathological correlates.
Parameter YKL-40 negative YKL-40 positive P c-Metnegative c-Met positive P
Sex M 18 29 0.974 13 27 0.619
F 11 18 10 16
Age mean 61 64 0.31 65 63 0.404
Tumor differentiation G1 3 0 0.018 1 0 0.229
G2 20 43 18 39
G3 6 4 4 4
Tumor invasion depth pT0 12 6 0.06 10 6 0.106
pT1 1 3 1 3
pT2 5 13 4 12
pT3 11 23 7 21
pT4 0 2 1 1
Lymph node metastasis N0 23 31 0.299 17 32 0.964
N1 6 16 6 11
TRG 1 12 6 0.006 10 6 0.01
2–5 17 41 6 37
Apoptosis absent 11 25 0.196 5 24 0.008
present 18 22 18 19
Abbreviations: F, female; M, male; TRG, tumor regression grade.
doi:10.1371/journal.pone.0123759.t002
Table 3. Univariate analysis for CRT response in 81 patients with locally advanced rectal cancer.
Parameter TRG1 TRG2-5 P
Sex M 11 41 0.323
F 9 20
Age mean 61 63 0.347
Tumor differentiation G1 1 3 0.624
G2 15 51
G3 4 7
Lymph node metastasis N1 18 41 0.08
N2 2 20
Apoptosis absent 7 32 0.205
present 13 29
YKL-40* positive 12 17 0.006
negative 6 41
c-Met* positive 10 13 0.01
negative 6 37
*: parameters included in the multivariate analysis: positive YKL-40: p = 0.004; positive c-Met: p = 0.007.
Abbreviations: F, female; M, male; TRG, tumor regression grade.
doi:10.1371/journal.pone.0123759.t003
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effective in predicting CRT response. Conversely, YKL-40 and c-Met were differentially ex-
pressed into the five TRG subclasses (Figs 3A and 4A).
In the TRG1 subgroup, the YKL-40 tumor expression ranged from 0 to 30% (mean: 7.7; me-
dian: 0), and that of c-Met ranged from 0 to 50% (mean: 12.5; median: 0); specifically YKL-40
and c-Met immunoreaction was absent in 67% and 62% of TRG1 cases, respectively. In the
group of partial responders (TRG2-5), the YKL-40 expression varied from 0 to 80% (mean:
Fig 3. Distribution of cases into to TRG classes according to YKL-40 immunoreactivity (A) and
overexpression of YKL-40 in the non-responder group (TRG2-5) when considered both as continuous
(B) and categorical variable (C).
doi:10.1371/journal.pone.0123759.g003
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17.65; median: 10), and that of c-Met ranged from 0 to 60% (mean: 23.3; median: 20). Even
when considered dichotomized variables, the expression of both biomarkers was significantly
associated with a lack of complete tumor regression: 87% of YKL-40-positive cases and 86% c-
Met-positive cases had a TRG2-5. The overexpression of YKL-40 and c-Met in the non-re-
sponder group (TRG2-5) compared with the responder group (TRG1) was statistically signifi-
cant, when considered both continuous (p = 0.01 and p = 0.05 or YKL-40 and c-Met
Fig 4. Distribution of cases into to TRG classes according to c-Met immunoreactivity (A) and
overexpression of c-Met in the non-responder group (TRG2-5) when considered both as continuous
(B) and categorical variable (C).
doi:10.1371/journal.pone.0123759.g004
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expression, respectively, Figs 3B and 4B) and categorical variables (p = 0.006 and p = 0.01, re-
spectively) (Figs 3C and 4C), and it had high positive predictive values (PPV = 87% and 86%
for YKL40 and c-Met, respectively) (Table 4).
To verify whether YKL-40 and c-Met co-expression could correlate with a partial or lack of
response to neoadjuvant treatment, all cases were stratified into three subgroups, according to
the expression of YKL-40 and c-Met on tumor biopsy: i: YKL-40-negative/c-Met-negative (13/
65 cases, 20%), ii: YKL-40-positive/c-Met-negative or YKL-40-negative/c-Met-positive (20/65
cases, 30%) and iii: YKL-40-positive/c-Met-positive (32/65 cases, 50%) (Fig 5).
Interestingly, 30 of the 32 rectal biopsies co-expressing both biomarkers were TRG2-5 on
surgical specimens (partial/absent response). This finding strengthens their positive predictive
value (94%).
Table 4. Predictive value of YKL-40 and c-Met as marker of chemo-radioresistance.
YKL-40 c-Met
TRG1 TRG2-5 TRG1 TRG2-5
Sensitivity 71% 74%
Specificity 66% 62%
Positive predictive value 87% 86%
Negative predictive value 41% 43%
Accuracy 70% 71%
doi:10.1371/journal.pone.0123759.t004
Fig 5. Stratification of cases into three subgroups, according to the expression of YKL-40 and c-Met on tumor biopsy:-/-: YKL-40-negative/c-Met-
negative;-/+: YKL-40-positive/c-Met-negative or YKL-40-negative/c-Met-positive and +/+: YKL-40-positive/c-Met-positive.
doi:10.1371/journal.pone.0123759.g005
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When cases were stratified as TRG1-2 vs. TRG3-5 the two biomarkers retained their predic-
tive value, although lower. In detail, 68% of YKL-40-positive cases (p = 0.03) and 65% of c-
Met-positive cases (p = 0.01) had a TRG3-5. Stratifying by TRG3, only c-Met retained its value
(p = 0.03).
Multivariate analysis confirmed YKL-40 and c-Met as independent predictive factors of
poor response to CRT (p = 0.004 and p = 0.007 for YKL-40 and c-Met, respectively).
4) Correlation of YKL-40 and c-Met expression with disease outcome
Follow-up data, ranging from 6 to 79 months (median: 40), were available for all but three pa-
tients. At the time of analysis, 75 (96%) of the patients were alive, but the remaining three (5%)
had died. Overall, recurrent disease after neoadjuvant CRT and surgery occurred in 21 patients
(28%) (Table 1). In addition, 11 patients (14%) experienced a local recurrence with a median
follow-up of 16 months.
All 20 patients identified as complete responders (TRG1) were alive at the time of last fol-
low-up (mean follow-up 52 months), as were 15 of the 16 patients classified as TRG2 (mean
follow-up 33 months); one patient in the TRG2 group was lost. The three deceased patients
had incomplete tumor response upon surgical rectal specimen (TRG 3, 4 and 5, respectively),
followed by tumor recurrence. Univariate survival analysis showed that high TRG was the only
parameter significantly correlated with a shorter overall survival (p = 0.01) and disease-free
survival (p = 0.004).
Discussion
In this study, we found that YKL-40 and c-Met immunohistochemical expression in pre-treat-
ment rectal cancer biopsies reliably predicts a partial or lack of response to neoadjuvant CRT
in patients with locally advanced rectal adenocarcinoma. Moreover, we demonstrated that c-
Met and YKL-40 are independent predictors of poor response to CRT and that Mandard TRG
is the only prognostic factor of poor survival.
Predictive role of YKL-40 and c-Met
To date, neoadjuvant CRT is the standard of care for patients with locally advanced (stages II
and III) rectal adenocarcinoma. However, its efficacy is quite unpredictable, with a complete
pathological response (ypT0) in up to 30% of cases[25,45,46]. Such a heterogeneous individual
response in patients with the same pT stage suggests a pivotal role of intrinsic biological prop-
erties of neoplastic lesions in determining CRT susceptibility and highlights the need for a
clinicopathological and molecular predictive stratification[25]. c-Met proto-oncogene codifies
the kinase tyrosine receptor hepatocyte growth factor (HGFR). Its genetic alterations have
been identified in a wide variety of solid cancers, and its expression is increased in metastatic
lesions[47] and in cancers of unknown primary origin[48]. As an oncogene, c-Met has a dual
effect on cancer cells[49]. On the one hand, it is a master driver of the long-term maintenance
of transformed neoplastic phenotype, making cancer cells dependent on its signaling for their
growth and survival. On the other hand, it acts as an expedient for cancer survival and dissemi-
nation, due to its overexpression in adverse microenvironmental conditions, such as hypoxia
[50] and therapeutic ionizing radiations[30,37,40,51]. In this regard, several authors demon-
strated an improvement in cellular sensitivity to radiation with c-Met inhibitors and siRNA
[30,37,52,53]. YKL-40, also termed chitinase-3-like-1, is a secreted glycoprotein that regulates
multiple cellular functions, including cell proliferation and differentiation, protection against
apoptosis, stimulation of angiogenesis, inflammation and extracellular tissue remodeling. High
plasma levels of YKL-40 were found in a wide spectrum of chronic inflammatory diseases and
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malignancies[54]. It is expressed by both tumor cells and their surrounding tumor-infiltrating
macrophages, stimulating the production of various tumor growth factors, including angiogen-
ic factors, cytokines, and chemokines. Although the overall pathological role and molecular
mechanisms of YKL-40 in tumorigenesis remains to be established, its angiogenic signature
has been reported to regulate tumor development in breast cancer, colon cancer and glioblasto-
ma [54,55]. Interestingly, ionizing radiations were shown to increase YKL-40 expression and
angiogenesis in a glioblastoma cell line, and this condition was reversed by a neutralizing YKL-
40 antibody[31]. Moreover, ionizing radiation and neutralizing YKL-40 antibody synergistical-
ly inhibited tumor growth in xenografted brain tumor models[34]. The aim of this multicentric
study was to verify the usefulness of c-Met and YKL-40 expression in identifying those patients
who will scarcely/not benefit from neoadjuvant CRT. c-Met and YKL-40 expression in biopsy
specimens had a highly positive predictive value, as they were associated with lack of complete
tumor response in 86% and 87% of cases, respectively (p = 0.01 and p = 0.006). Interestingly,
this observation was further reinforced when only co-expression was considered: 94% of the
rectal biopsies co-expressing both biomarkers showed TRG2-5.
Stratifying patients according to TRG2, both YKL-40 and c-Met retained their predictive
value (p = 0.03 and p = 0.01 for YKL-40 and c-Met respectively), whereas stratifying by TRG3
c-Met only proved to predict therapy efficacy (p = 0.03).
Such a result is in line with the ‘stress-response’ role of the two molecules: tumors highly ex-
pressing c-Met and YKL-40 will most likely not benefit from CRT because these cancer cells
have already switched on a transcriptional adaptation to unfavorable microenviromental con-
ditions. The decision to use an immunohistochemical approach instead of a molecular analysis
provides practical advantages. Genomic and proteomic analyses are expensive, and special
equipment and highly trained technicians are required to perform certain molecular analyses,
whereas immunohistochemistry is widely employed in diagnostic routines and has a favorable
cost-benefit balance. Based on the previous external validation of these multi-institutional re-
sults, the introduction of an immunohistochemistry-based panel composed of YKL-40/c-Met
in rectal cancer diagnostic-routine in parallel to H&E-stained slides could be used to avoid ex-
cessive costs even in laboratories managing a high number of surgical specimens.
Prognostic role of clinical and pathological variables
The role of c-Met in prognosis has been reported to correlate with its overexpression in differ-
ent solid tumors (such as gastric adenocarcinoma[51], ovarian[56] and non-small lung cancer
[57]; the overexpression of YKL-40, particularly as a circulating marker[54], is similarly corre-
lated with its role in prognosis. Nevertheless, our results do not support the reported prognostic
role for c-Met and YKL-40[58] in colorectal cancer[32,39,41,59], although the latter was de-
scribed only at the serum level. We found that TRG, quantified in five grades according to the
Mandard scale[43], was the sole parameter influencing patient outcome in terms of both over-
all survival and disease-free survival, as previously reported[60–62]. Accordingly, patients clas-
sified as TRG1 (complete tumor response) and TRG2 (single cells or small groups of cancer
cells) showed a better overall survival (100% at the time of last follow up in both groups) and
control of disease progression (84,2% in TRG1 group and 80% in TRG2 group). Although the
prognostic and predictive significance of TRG is still influenced by the limited end points and
the quality and heterogeneity of histological data, TRG following preoperative chemora-
diotherapy for rectal cancer has a solid prognostic evidence. A future challenge remains to dis-
cover a surrogate noninvasive method to surgery to accurately identify patients who have
obtained a favorable TRG and to use TRG to select patients for postoperative adjuvant chemo-
therapy following preoperative CRT[63].
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Conclusion
YKL-40 and c-Met expression in pre-neoadjuvant rectal cancer biopsy is a reliable tool to pre-
dict the partial or lack of tumor response to CRT. Accordingly, an “immunohistochemistry-en-
riched” diagnostic approach to rectal biopsies, aimed at increasing CRT sensitivity using
specifically selected targeted therapies for those expected to be poor responders, could provide
predictive information with cost-benefit efficacy and facilitate the further therapeutic selection
of patients.
Finally, prospective randomized trials are necessary to validate the role of YKL-40/c-Met in
predicting tumor resistance; if so, the efficacy of neoadjuvant CRT in these patients would ben-
efit of therapy sensitizers, i.e. targeted c-met inhibitors, to improve responsiveness.
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